UK patients with vision loss confused by ‘disjointed’ benefits registration system

Article

Accessibility obstacles could prevent those with sight loss from receiving support and care.

A physician helps a man in sunglasses during an office visit. ©Elnur – stock.adobe.com

Sight-impaired patients in the UK report many barriers to receiving assistance. Photo credit: ©Elnur – stock.adobe.com

In the United Kingdom, registering for a Certificate of Vision Impairment (CVI) is intended to provide access to benefits. But for many citizens, the ‘disjointed’ certification process actually make it more difficult to obtain healthcare, support services and rehabilitation. Professor Shahina Pardhan, Director of the Vision and Eye Research Institute at Anglia Ruskin University (ARU), was lead author for the study, which was published in Eye.1

There are two distinct levels of CVI: sight impaired (partially sighted) and severely sight impaired (blind). A CVI enables the patient to register locally for support services, through a Referral of Vision Impairment (RVI). Receiving the certification is a laborious process – an ophthalmologist completes registration which is then approved by the patient’s primary physician, the local authority and The Royal College of Ophthalmologists Certifications Office.

But simply being certified does not trigger public assistance. Registration is voluntary, but it is another step that is required for sight-impaired patients to access services. Those benefits range from transportation to cleaning and cooking services, as well as financial aid and medical assistance.

The 17 participants in the study reported there were many barriers to care. Some were not certain how to register these services, or which they were qualified for based on their needs. Receiving certification was challenging for some patients, who found certain practitioners more likely to issue certification than others.

Even in cases where patients did receive a CVI and a referral to benefits, they faced long waitlists. One patient reported they registered for support services due to sensory impairment but did not hear back after a full year. Others said they did not know who was meant to be their point of contact for scheduling and coordinating services.

“It is clear from our research that many feel the process of registration and certification is disjointed, creating a barrier for people with sight loss,” Pardhan said.2 The researchers indicated that CVI-qualified patients deserved more clarity on a local and national level.

“More timely, efficient, and effective provision of information, advice, and signposting to relevant support services in local social care and third sector organisations, along with more informed decisions around certification and registration by eye health professionals, will benefit patients and improve their wellbeing and quality of life,” Pardhan said.

References

1. Pardhan, S., Driscoll, R., Ingleton, H. et al. Confusion around Certification of Vision Impairment (CVI) and registration processes—are patients falling through the cracks? Eye. April 19, 2023. Accessed May 24, 2023. https://doi.org/10.1038/s41433-023-02520-0
2. People with sight loss confused by ‘disjointed’ system. News release. Anglia Ruskin University, May 24, 2023.
Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.